blog.panalgo.com
Open in
urlscan Pro
2606:2c40::c73c:67e2
Public Scan
Submitted URL: https://info.panalgo.com/e3t/Ctc/W1+113/cMwSz04/VVv_p23WG7gYW4m-2RB8nzz-7VQq1454P-Y-5N6pj1X33q3nJV1-WJV7CgG2jW5J4JDG3YH28...
Effective URL: https://blog.panalgo.com/blog/qanda-with-gregnorman-and-poorvanemlekar?utm_campaign=Blog&utm_medium=email&_hsmi=225765008...
Submission: On September 15 via api from US — Scanned from DE
Effective URL: https://blog.panalgo.com/blog/qanda-with-gregnorman-and-poorvanemlekar?utm_campaign=Blog&utm_medium=email&_hsmi=225765008...
Submission: On September 15 via api from US — Scanned from DE
Form analysis 3 forms found in the DOM
GET https://panalgo.com/?s
<form role="search" method="get" class="search-form" action="https://panalgo.com/?s" data-hs-cf-bound="true">
<label>
<input type="search" class="search-field" placeholder="Search" value="" name="s" required="">
</label>
<input type="submit" class="search-submit" value="Search">
</form>GET https://panalgo.tankdesign.com/?s
<form role="search" method="get" class="search-form" action="https://panalgo.tankdesign.com/?s" data-hs-cf-bound="true">
<label>
<input type="search" class="search-field" placeholder="Search" name="s">
</label>
<input type="submit" class="search-submit" value="Search">
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/6379752/7fd6f983-80bb-4d6d-b1fe-463058276ce9
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/6379752/7fd6f983-80bb-4d6d-b1fe-463058276ce9" enctype="multipart/form-data"
id="hsForm_7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" method="POST"
class="hs-form stacked hs-form-private hsForm_7fd6f983-80bb-4d6d-b1fe-463058276ce9 hs-form-7fd6f983-80bb-4d6d-b1fe-463058276ce9 hs-form-7fd6f983-80bb-4d6d-b1fe-463058276ce9_56e1b3d4-a5de-4c2a-bb86-7af707827e0a"
data-form-id="7fd6f983-80bb-4d6d-b1fe-463058276ce9" data-portal-id="6379752" target="target_iframe_7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" data-reactid=".hbspt-forms-0" data-hs-cf-bound="true">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-0.1:$0"><label id="label-email-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" class="" placeholder="Enter your Email"
for="email-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" data-reactid=".hbspt-forms-0.1:$0.0"><span data-reactid=".hbspt-forms-0.1:$0.0.0">Email</span><span class="hs-form-required" data-reactid=".hbspt-forms-0.1:$0.0.1">*</span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-0.1:$0.$email"><input id="email-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" class="hs-input" type="email" name="email" required="" placeholder="" value="" autocomplete="email"
data-reactid=".hbspt-forms-0.1:$0.$email.0" inputmode="email"></div>
</div>
<div class="hs_blog_bhe_blog_12739941668_subscription hs-blog_bhe_blog_12739941668_subscription hs-fieldtype-radio field hs-form-field" style="display:none;" data-reactid=".hbspt-forms-0.1:$1"><label
id="label-blog_bhe_blog_12739941668_subscription-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" class="" placeholder="Enter your Notification Frequency" for="blog_bhe_blog_12739941668_subscription-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798"
data-reactid=".hbspt-forms-0.1:$1.0"><span data-reactid=".hbspt-forms-0.1:$1.0.0">Notification Frequency</span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$1.1"></legend>
<div class="input" data-reactid=".hbspt-forms-0.1:$1.$blog_bhe_blog_12739941668_subscription"><input name="blog_bhe_blog_12739941668_subscription" class="hs-input" type="hidden" value=""
data-reactid=".hbspt-forms-0.1:$1.$blog_bhe_blog_12739941668_subscription.0"></div>
</div>
<div class="hs_lifecyclestage hs-lifecyclestage hs-fieldtype-radio field hs-form-field" style="display:none;" data-reactid=".hbspt-forms-0.1:$2"><label id="label-lifecyclestage-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" class=""
placeholder="Enter your Lifecycle Stage" for="lifecyclestage-7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" data-reactid=".hbspt-forms-0.1:$2.0"><span data-reactid=".hbspt-forms-0.1:$2.0.0">Lifecycle Stage</span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$2.1"></legend>
<div class="input" data-reactid=".hbspt-forms-0.1:$2.$lifecyclestage"><input name="lifecyclestage" class="hs-input" type="hidden" value="subscriber" data-reactid=".hbspt-forms-0.1:$2.$lifecyclestage.0"></div>
</div><noscript data-reactid=".hbspt-forms-0.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-0.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-0.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-0.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-0.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":1277.400001525879,"rumServiceResponseTime":1514.7999992370605,"rumFormRenderTime":1.9000015258789062,"rumTotalRenderTime":1517.6000022888184,"rumTotalRequestTime":235.1999969482422,"embedAtTimestamp":"1663258242076","formDefinitionUpdatedAt":"1595797927397","pageUrl":"https://blog.panalgo.com/blog/qanda-with-gregnorman-and-poorvanemlekar?utm_campaign=Blog&utm_medium=email&_hsmi=225765008&_hsenc=p2ANqtz-9af-w9Y-0YZnNqXT8TJ8QObMQrYZ6ZqWhI34tBh03PCP1pm_TOBOadZtHIxNOE6RU4oIHXu2H81hxCXSTq5nTNGb5acg&utm_content=225765008&utm_source=hs_email","pageTitle":"Insights & Innovators: A Q&A with Greg Norman and Poorva Nemlekar from Dexcom","source":"FormsNext-static-5.530","sourceName":"FormsNext","sourceVersion":"5.530","sourceVersionMajor":"5","sourceVersionMinor":"530","timestamp":1663258242082,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/105.0.5195.125 Safari/537.36","originalEmbedContext":{"portalId":"6379752","formId":"7fd6f983-80bb-4d6d-b1fe-463058276ce9","formInstanceId":"4798","pageId":"84704233508","region":"na1","pageName":"Insights &amp; Innovators: A Q&amp;A with Greg Norman and Poorva Nemlekar from Dexcom","contentType":"blog-post","formsBaseUrl":"/_hcms/forms/","inlineMessage":true,"target":"#hs_form_target_subscribe_blog_4798","formData":{"cssClass":"hs-form stacked"}},"canonicalUrl":"https://blog.panalgo.com/blog/qanda-with-gregnorman-and-poorvanemlekar","pageId":"84704233508","pageName":"Insights &amp; Innovators: A Q&amp;A with Greg Norman and Poorva Nemlekar from Dexcom","formInstanceId":"4798","urlParams":{"utm_campaign":"Blog","utm_medium":"email","_hsmi":"225765008","_hsenc":"p2ANqtz-9af-w9Y-0YZnNqXT8TJ8QObMQrYZ6ZqWhI34tBh03PCP1pm_TOBOadZtHIxNOE6RU4oIHXu2H81hxCXSTq5nTNGb5acg","utm_content":"225765008","utm_source":"hs_email"},"renderedFieldsIds":["email"],"formTarget":"#hs_form_target_subscribe_blog_4798","correlationId":"f3f9f13a-bdf6-4444-bb80-bf31f904399b","contentType":"blog-post","hutk":"9f4ab66c64c1f725850424cd827abe57","captchaStatus":"NOT_APPLICABLE","isHostedOnHubspot":true}"
data-reactid=".hbspt-forms-0.7"><iframe name="target_iframe_7fd6f983-80bb-4d6d-b1fe-463058276ce9_4798" style="display:none;" data-reactid=".hbspt-forms-0.8"></iframe>
</form>Text Content
This website stores cookies on your computer. These cookies are used to improve
your website experience and provide more personalized services to you, both on
this website and through other media. To find out more about the cookies we use,
see our Privacy Policy.
We won't track your information when you visit our site. But in order to comply
with your preferences, we'll have to use just one tiny cookie so that you're not
asked to make this choice again.
Accept Decline
* IHD Analytics
* IHD Analytics
* IHD Data Science
* Training & Support
* Modeling & Strategy
* News & Events
* Publications
* Press Releases
* Thought Leadership
* Resources
* Company
* Our Story
* Our Team
* Careers, Culture and Benefits
* Blog
* Contact
< Back to Insights & Innovators
Q&A
September 15, 2022
By Team Panalgo
INSIGHTS & INNOVATORS: A Q&A WITH GREG NORMAN AND POORVA NEMLEKAR FROM DEXCOM
Greg Norman, PhD is Director of Health Economics and Outcomes Research at Dexcom
where he leads studies to assess real-world evidence of the clinical and health
economic impact of continuous glucose monitors for people with diabetes. Poorva
Nemlekar, MS is the Lead HEOR Specialist within the Global Access team at
Dexcom. Poorva works on multiple aspects of outcomes research including the
execution of real-world evidence studies, evidence gap analysis, and systematic
literature reviews.
In part one of this two-part blog series, Greg Norman and Katia Hannah
introduced us to their team’s research and discussed one study they conducted in
IHD. In this second and final part of the series, we’ll hear more about the
team’s exploratory work and insights from the study titled Association Between
Change in HbA1c and Professional CGM Use in Adults with Type 2 Diabetes on
Non-Insulin Therapies – A Real-World Evidence Study. Read on for Greg and
Poorva’s insights.
Q: In part 1, you told us about your team’s work analyzing real-world data on
continuous glucose monitors (CGMs), but can you talk a little more about the
value of real-world data analytics for exploratory work?
Greg: Like I said, at Dexcom, we use real-world evidence studies to complement
our clinical trial work, since clinical trials take significant amounts of time
and money. Ever since we started using IHD about a year ago, we have been able
to do more exploratory work by having the data and analytics capabilities
readily available. For example, we recently conducted a study focused on
professional CGMs in patients with T2D not on insulin, which is an area of
research that was previously unexplored. With the analysis of real-world data,
we were able to explore what the value of CGMs might be in this population.
Exploratory studies like this one could help with things like label expansion,
identifying unmet need, and finding patients who might need our device in the
future.
Q: Poorva, can you tell us a little about this study, Association Between Change
in HbA1c and Professional CGM Use in Adults with Type 2 Diabetes on Non-Insulin
Therapies – A Real-World Evidence Study?
Poorva: There are two types of CGM devices – personal and professional – and in
contrast to the study that Katia discussed in part 1, which focused on personal
CGMs, this one analyzed professional CGM use. A personal CGM is the patient’s
own device used to manage their diabetes. The professional CGM is given to the
patient by their provider and often in a blinded mode to monitor their glucose
patterns over a 10-day period.
The effects of professional CGM use in real-world settings have not been studied
much in the T2D population. Furthermore, there is very limited information on
patients with Type 2 diabetes in poor glycemic control using two or more
non-insulin therapies but not using insulin. Given this background, we conducted
a retrospective observational database study assessing the glycemic effect of
professional CGM use in this particular Type 2 diabetes population.
Q: What did the results show and why are they significant?
Poorva: We first observed statistically significant reductions in HbA1c, an
indicator of blood glucose levels, in CGM users after device initiation. This
result is significant because it indicates that CGM devices such as the Dexcom
G6 can be useful in the Type 2 population not using insulin, something that has
been relatively unexplored to this point.
We then looked at subsequent insulin use. This study started with a cohort of
all non-insulin users and in the follow-up, we saw that 20% of CGM users were on
insulin compared to just 10% in the non-user group. These results indicate that
more reliable glucose monitoring can help providers make more informed decisions
about care and help them identify when their patients need insulin or a tweak to
their medication.
Next, we would like to explore professional CGMs in other diabetic subgroups
where there is not yet much real-world evidence.
Q: What is the broader impact of this study?
Poorva: One insight I find particularly interesting is the fact that after
device initiation, CGM users were more likely to be on insulin than non-users,
but even for patients who did not start insulin there was a greater decrease in
HbA1c for the CGM users compared to the non-users. This suggests the insights
from the CGM may have helped health care providers to counsel their patients
about lifestyle changes and medication adherence. Overall, the findings suggest
that more reliable and regular glucose monitoring can help patients realize when
they need insulin or certain changes to their care. From our perspective, this
provides important evidence to providers to consider recommending CGMs to their
patients sooner and more frequently.
Q: How did IHD impact the success of this study and your other research beyond
this study?
Greg: This is our first year using IHD and previously, we weren't doing any
internal analyses or licensing any data. We were always outsourcing our
analytics work so it was difficult to get exploratory work like this study
completed. This is the first time we've had the chance to do our own analyses
and using IHD let us get up and running much quicker than we would have if we
were attempting to do work in SAS or outsourcing the work.
Poorva: On a more general note, I would also mention that we often have to
create demo projects for our diabetes research, and it becomes easier to run the
analyses when we have these demo projects already set up in the IHD platform.
Greg: Also, we talked about how quickly we onboarded, which allowed us to
generate many impactful real-world evidence studies in just one year. But
something that I didn’t expect was also how IHD can help with ad hoc questions
and analyses. We have been able to run quick queries to provide valuable
business insights in real-time to inform decision-making. That has really been
impactful for us since that wasn’t easy with outsourcing.
If you haven't read part 1 of this blog series, click here to read now.
--------------------------------------------------------------------------------
Contact us to learn how Panalgo's IHD Analytics platform can help your RWE teams
scale their analytics capabilities and deliver richer insights, faster.
* Twitter
* LinkedIn
* Email
SUBSCRIBE TO BLOG
Email*
Notification Frequency
Lifecycle Stage
Panalgo, formerly BHE, provides software that streamlines healthcare data
analytics by taking complex programming out of the equation, enabling users to
focus on what matters most – turning data into insights. Our Instant Health Data
(IHD) software empowers teams to generate and share trustworthy results faster,
leading to improved data- and evidence-driven decisions.
GET IN TOUCH
265 Franklin St Suite 1101
Boston, MA 02110
(781) 290-0808
sales@panalgo.com
* Quick Links
* IHD Analytics
* Modeling & Strategy
* News & Resources
* Careers, Culture and Benefits
© 2022 Panalgo, LLC. All Rights Reserved.
* Privacy Policy
* Acceptable Use Policy
*
*